TUMOR LYSIS SYNDROME DURING SELPERCATINIB TREATMENT IN A PATIENT WITH MEDULLARY THYROID CANCER. De Leo S, Trevisan M, Re Sarto GV, Moneta C, et al. Thyroid 2023 Jul 18. doi: 10.1089/thy.2023.0214.

Read + Share

Amedeo Smart

Independent Medical Education

De Leo S, Trevisan M, Re Sarto GV, Moneta C, et al. TUMOR LYSIS SYNDROME DURING SELPERCATINIB TREATMENT IN A PATIENT WITH MEDULLARY THYROID CANCER. Thyroid 2023 Jul 18. doi: 10.1089/thy.2023.0214.
PMID: 37463111